Indian Institute of Science, Bangalore, incubated startup Mynvax signed definitive agreements to raise $4.2 million in its Series A funding round led by Accel. LetsVenture, 1Crowd, Kotak Investment Advisors, and a few early-stage angel investors also participated in this round.
According to the official statement, the funds will be deployed to further the clinical development of Mynvax's novel recombinant vaccines for COVID-19 and human influenza.
